Member Info for Timster

We know what's coming, CE Mark , just paperwork to complete for most accurate test produced in the world to date. Then contracts to follow that big Al is only worried about not being able to make enough tests to fulfill. That's puts us in a pretty good place in my book????

Keep going markb you're doing a great job

He didn't say that at all, have a listen I just posted the webinar

https://avacta.com/preliminary-results-for-the-year-ending-31-december-2020-webinar-presentation/

Slide 20

Not sure the narrative has changed just seems that particular Twitter user is catching up on avacta, they seem to be mostly SYME until very recently

Hardly any demand then, it's definately nearly gone...

Been discussed in the thread only 327m with 30% profit

Stiefel have said 30% profit expectation in their notes”

Ok same data as it seems reasonable that’s 327.3m profit in first year at 30%!

Obviously it’s an IF but that’s why ‘we’ are here or a profit (not earnings) per share of 1.29!

At £10/share that’s still a single figure pe. It is quite incredible really!

Usual caveats

Trek

Bloody doctors! That's not what ndn says and he's way better...

Ah yes, 100% kong that's why doh/maatt (bless his soul) was banging on about European markets giving us a larger profit margin and up yours to UK gov.
Would be embarrassing for UK if Europe start using the best LFT on the market created by a British firm but the British continue to use Chinese crap

@kong what he said about the UK is the gov offer them free of charge so there is little market for selling a test outside of this. So this is the path to commercialisation in the UK. That doesn't mean the government get them for free, have you forgotten the 8bn dps contract now in place?
https://bidstats.uk/tenders/2021/W09/746193438

Avacta are a small company without the limitless resources of someone like Roche. Despite this they have created the most accurate LFT in the world. Roche have created a ****e one.

So the question is once we have CE marking which test would governments around Europe and the world want to be buying?

Don't forget too innova is only approved for professional use it got fudged through a special MHRA dispensation to be used as a self test. Nothing to do with Innova.

I thought exactly the same, space program and billion dollar nuclear submarines

India is on the low to middle income list:
https://wellcome.org/grant-funding/guidance/low-and-middle-income-countries
As per the mologic collaboration RNS so they would look to supply at cost, so no good to our share price but very good for India

Why would Avacta be "very pleased with demand they are hearing about" and "more concerned about product supply than demand" if it was all doom and gloom.

Or do you think they are just haming it up?

Yep that would be a great feature enhancement to filter threads

Up on avacta website now

https://avacta.com/preliminary-results-for-the-year-ending-31-december-2020-webinar-presentation/

Nothing continued part III:
On 7 January 2021, we announced the licensing agreement with Point Biopharma Inc to provide access to Avacta’s pre|CISION™ technology for the development of tumour-activated radiopharmaceuticals.
Key appointments of Head of Chemistry, Manufacturing and Controls (CMC), Head of Clinical Operations and Head of Translational Sciences will together manage an extensive outsourced network of drug development service providers.
On 1 February 2021, AffyXell Therapeutics (‘AffyXell’), the partnered programme with Daewoong Pharmaceuticals (‘Daewoong’), closed a series A venture capital investment of $7.3m to further develop its pipeline of next generation cell and gene therapies.
On 18 February 2021, the Medicines and Healthcare products Regulatory Agency (‘MHRA’) approved the CTA for AVA6000 pro-doxorubicin for a phase I, first-in-human, open label, dose-escalation and expansion study in patients with locally advanced or metastatic selected solid tumours. The Group anticipates dosing first patients in mid-2021 subject to COVID-19 restrictions on hospital resources with first pharmacokinetics read-out possible before the year end.
Financial and Corporate highlights

Fundraisings completed during the period raising £53.8 million to expand Diagnostics and Therapeutics programmes.
Cash and short-term deposit balances at 31 December 2020 of £47.9 million (31 December 2019: £8.8 million)
Revenues of £3.6 million for year ended 31 December 2020 (17-month period to 31 December 2019: £5.5 million)
Operating loss of £21.3 million for year ended 31 December 2020 (17-month period to 31 December 2019: £18.0 million)
Increased R&D investment across diagnostics and therapeutic programmes, leading to reported loss of £18.9 million (17-month period to 31 December 2019: £15.6 million)
Loss per ordinary share 8.4p (17-month period to 31 December 2019: 13.0p)
Paul Fry appointed as Non-executive Director. Paul is Chief Financial Officer of Vectura Group plc, an industry-leading inhaled drug delivery specialist listed on the FTSE Main Market.

Nothing continued :
On 8 February 2021, we established a commercial partnership with Mologic following several months’ collaborative work to provide Avacta with a faster route to market for the lateral flow rapid antigen test by CE marking it for professional use under Mologic’s existing ISO13485 quality system. The CE mark will then be transferred to Avacta after it receives ISO13485 accreditation, which is expected in April 2021.
The collaboration with Mologic also provides initial manufacturing capacity with the benefit of a short set-up time for the lateral flow test with Global Access Diagnostics (‘GAD’), in addition to the agreements with BBI Group, Abingdon Health and others, that will provide manufacturing capabilities that can be scaled to several millions of tests per month.
On 9th March 2021, we announced a royalty bearing license agreement with Biokit, a Werfen Company, to develop and commercialise an Affimer-based in-vitro diagnostic test.
Operating highlights – Therapeutics

Established a partnered programme (‘AffyXell Therapeutics’) in South Korea with Daewoong Pharmaceutical Co. Ltd., to develop the next generation of cell and gene therapies, incorporating Affimer® proteins to enhance the immune-modulatory effects. Programme subsequently expanded to provide access to the Affimer® platform for neutralising Affimer® therapies for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future global pandemics.
Demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, ‘TMAC®’, in a pre-clinical animal model of cancer.
Expanded the existing multi-target collaboration and development agreement with LG Chem Life Sciences (‘LG Chem’) to include new programmes incorporating Avacta’s Affimer XT™ serum half-life extension system, deal worth up to $98.5 million plus royalties.
Appointment of Neil Bell as Chief Development Officer responsible for the late stage pre-clinical and early clinical development of Avacta’s pipeline of pre|CISION™ pro-drugs and Affimer®
Submitted the Clinical Trial Authorisation (CTA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a phase I dose-escalation and expansion study of AVA6000 pro-doxorubicin, Avacta’s first pre|CISION™ FAP-activated prodrug.
On schedule to select the next pre|CISION™ prodrug chemotherapy clinical development candidate from the pipeline by the end of 2021.
Significant progress with in-house Affimer® bispecific programmes towards selection of a clinical development candidate by the end of 2021. Two new programmes initiated, building on the AVA004 PD-L1 antagonist programme: AVA027, a PD-L1/TGfß receptor trap combination, and AVA028, a PD-L1/IL2 bispecific.
Post-period highlights – Therapeutics

On 7 January 2021, we announced the licensing agreement with Point Biopharma Inc to provide access to Avacta’s pre|CISION™ technology for the development of tumour-activated

Yep I'm with mortgage literally nothing has happened

Operating highlights – Diagnostics

Rapid generation of a range of Affimer® reagents that bind the SARS-CoV-2 coronavirus spike antigen for diagnostic testing applications.
Collaboration with several partners to develop a rapid test for the COVID-19 infection for mass population screening.
Appointed BBI Solutions, part of BBI Group (‘BBI’), and Abingdon Health to manufacture the saliva-based rapid SARS-CoV-2 antigen test.
Entered a collaboration with the Liverpool School of Tropical Medicine (‘LSTM’) to provide analytical and clinical validation of the rapid coronavirus antigen test.
Announced launch of an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Collaboration with Adeptrix (Beverly, MA, USA) to develop a high throughput Affimer-based SARS-CoV-2 antigen bead-assisted mass spectrometry test (‘BAMSTM’ test) to be used on hospitals’ existing installed base of mass spectrometers to diagnose COVID-19 infection. Initiated clinical evaluation of BAMS™ SARS-CoV-2 antigen test at a UK NHS hospital site.
Exclusive distribution agreement announced with Medusa19 Limited (‘Medusa19’) for direct-to-consumer sales of a rapid antigen self-test for Covid-19.
Major licensing agreement with Astrea Bioseparations Limited (‘Astrea’) for the use of the Affimer® platform in affinity purification applications.
Successfully passed first audit by the Group’s Notified Body (BSI Group) of the Company’s Quality Management System as first step in establishing ISO13485 accreditation, a critical quality assurance system for a developer and legal manufacturer of diagnostic products and medical devices. The final audit will take place in April 2021.
Strengthened and expanded diagnostics management team with the appointment of a Product Manager, Head of Product Development and Operations Director.
Post-period highlights – Diagnostics

AffiDX® SARS-CoV-2 Antigen Lateral Flow Test shows excellent analytical sensitivity of 50 pg/ml of S1 spike protein with a read time of 20 minutes. As far as the Group is aware and on the basis of laboratory testing to date, this is currently the most sensitive S1 spike lateral flow test available. On 16 February 2021, we announced the initial clinical evaluation of this test using anterior (front) nasal swab samples (30 positive and 26 negative samples) which demonstrated a sensitivity of 96.7% for samples with an infectious viral load (PCR Ct value < 26) and a specificity of 100%. Subsequently, on 20 April we announced the completion of the clinical validation of the AffiDX® SARS-CoV-2 antigen lateral flow test with excellent performance data (clinical sensitivity of 98.0% for samples with Ct values up to 31 and clinical specificity of 99.0%).
On 28 January 2021, we entered a collaboration agreement with Bruker Corporation to evaluate the clinical utility and commercial potential of the B

https://bit.ly/3erzawO
25min 30 seconds in